



PRESS RELEASE

October 16, 2009

Glasgow's ClinTec International expands MENA operation with new Cairo office launch

- *British firm at the forefront of efforts to open up pharmaceuticals and biotechnology sectors in the Middle East and North Africa region*
- *New Egyptian presence provides global pharma firms with access to our unrivalled knowledge of regional regulatory requirements, understanding of local cultures, says ClinTec President and CEO Dr Rabinder Buttar*

ClinTec International, Scotland's leading global clinical research organisation (CRO), has launched its Cairo office. The new operation not only provides ClinTec International's global biopharmaceutical associates with access to new patient populations, but it also further consolidates the privately-owned company's reputation as a major presence in the Middle East and North Africa (MENA) region.

"The launch of the new office cements ClinTec International's reputation as one of the few truly global providers of quality assured clinical research services," said its founder, President and CEO, Dr Rabinder Buttar. "It also reflects the increasing importance of Egypt – and wider MENA region – to the global clinical research market too."

With a presence in almost 40 countries around the world, including Bangalore (India) and Dubai (UAE), Glasgow-headquartered ClinTec International manages clinical trials in all major therapeutic areas, including oncology, neurology, cardiovascular, respiratory as well as gastroenterology. It also has a wealth of experience in providing consultancy services in all aspects of quality assurance (QA), with ClinTec's QA team having all held senior positions within quality and manufacturing operations in the pharmaceutical, biotechnology and medical devices industries.

"With major international pharma firms now outsourcing clinical trials activities to new and emerging markets, quality assurance expertise has become increasingly vital to ensure all trials-related processes are independently verified," said Gráinne Forrest, ClinTec International's Head of Quality Assurance who was in Cairo for the office launch.

"Any expansion of Egypt's promising pharmaceuticals sector will, however, also draw attention to the need for internationally acceptable regulatory standards. ClinTec International's highly experienced QA personnel are now ready to share expertise with our new Egyptian colleagues," added Ms. Forrest.

"Our Cairo office launch received overwhelming support from medical directors from all the major pharmaceutical firms with a presence in the region," said Dr Buttar. "Our unrivalled local expertise, including our knowledge of regional regulatory requirements and cultures, is our strength and it means the major



pharmaceutical firms know they can always turn to us wherever in the world we operate – and indeed wherever in the world they want to operate, too.

“While North America and the European Union constitute the bulk of pharmaceutical sales and clinical research development, Egypt and the wider MENA region are growing at a phenomenal pace and are estimated to be worth some US\$10bn (£6.6bn) currently,” added Dr Buttar. “At ClinTec we are proud to be at the forefront of opening up new and emerging markets and are delighted now to be helping to develop crucial expertise in Egypt and beyond.”

- ENDS -

Notes to Editors

About ClinTec International

ClinTec International is a global contract clinical research organisation, which was established in 1997 by Dr Rabinder Buttar, the company’s President and CEO. ClinTec International has a presence in almost 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, India and the US.

In addition to ClinTec International’s vast expertise in oncology, the organisation has also conducted over 150 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec International’s ‘fast, flexible and focused’ approach to clinical research ensures an added advantage to the drug development process. The organisation’s range of services includes Clinical Monitoring and Project Management, Regulatory Affairs, Medical Writing, Data Management and Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.

ClinTec Media:

To speak to, or arrange an interview with Dr Rabinder Buttar, please contact ClinTec International’s media team at:

John Macgill or Andrew Ritchie: + 44 (0) 131 556 0050 (including out of hours).

Website: www.clintec.com